[Hepatitis C antibodies in non-A, non-B hepatitis patients and members of HIV risk groups (pilot study)].
In a multi-center study sera from NANB-hepatitis (NANBH) patients and members of so-called HIV-risk groups (homosexuals, i.v.-drug abusers, hemophiliacs) were investigated by the recombinant-based HCV-antibody EIA, 74.4% of chronic NANBH-patients and 20% of acute NANBH patients were anti-HCV reactive, 33.3% of HIV-1-positive homosexuals, 43.5% of i.v.-drug abusers and 73.5% of hemophiliacs. The true prevalence of infection remains to be determined by a second, independent (confirmatory) test.
Kühnl
P
P
Abt. f. Transfusionsmedizin u. Transplantationsimmunologie, Univ.-Klinik Hamburg.
Roggendorf
M
M
Stangel
W
W
Seidl
S
S
Laufs
R
R
Sibrowski
W
W
Bornhövd
K
K
Polywka
S
S
Kalmar
G
G
Deinhardt
F
F
D000914:Antibodies, Viral / Q000032:analysis*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D006679:HIV Seropositivity / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D006467:Hemophilia A / Q000276:immunology*; D016174:Hepacivirus / Q000276:immunology*; D006526:Hepatitis C / Q000175:diagnosis* / Q000276:immunology; D006716:Homosexuality; D006801:Humans; D008297:Male; D010865:Pilot Projects; D012307:Risk Factors; D015819:Substance Abuse, Intravenous / Q000276:immunology*
D000914:Antibodies, Viral
HCV-Antikörper bei NANBH-Patienten und HIV-Risikogruppen-Angehörigen (Pilotstudie).